Source Treatment n % female Mean Age Treatment Length Measure Design Response Rate Odds Ratiob Odds Ratioc Lower Limitc Upper Limitc
Amitriptyline      
Birmaher et al.[50] 13 70 16.1 10 HDRS RCT 69% 0.900b 2.625c .527 13.068
Kashani et al.[35] 9 11 10.8 8 BDI RCT 67% 7.000b 2.500c .370 16.888
Kye et al. [51] 12 29 14.6 8 HAM-D RCT 92% 1.222b 11.00c 1.061 114.086
Total 34

 

 

 

 

 

 76% 1.825b 3.523c 1.179 10.568
Alprazolam      
Bernstein et al. [52] 9 70 14.12 8 CGI-I Comp. 67% - 2.500c .370 16.888
Total 9           67% - 2.500c .365 17.122
Bupropion      
Glod et al. [53] 11 45 15.5 8 CGI-I Open 73% - 3.200c .540 18.980
Total 11           73% - 3.200c .532 19.262
Citalopram      
Shirazi&
Alaghband-Rad [54]		 30 53 13.6 6 HDRS Open 73% - 2.750 c .934 8.100
Schirman et al. [55] 51 50.5 13.9 8 CGI-I Open 55% - 1.266c .581 2.757
Von Knorring et al. [56] 83 74 14.1* 12 KSADS RCT 60% 0.967b 1.552 c .839 2.871
Wagner et al. [57] 89 53 12 8 CDRS-R RCT 36% 1.825b 0.574c .315 1.046
Total 253           52% 1.311b 1.117c .776 1.645
Clomipramine      
Braconnier et al. [58] 55 54 16 8 CGI-I Comp. 58% - 1.443c .680 3.063
Total 55           58% - 1.443c .657 3.169
Desipramine      
Boulos et al. [59] 12 55.3* 17.5 6 HAM-D RCT 50% 2.000b 1.000 c .202 4.955
Klein et al. [60] 23 67 15.7 6 CGI-I RCT 52% 1.576b 1.190 c .374 3.785
Kutcher et al. [61] 30 70 17.8 8 HDRS RCT 47% 1.511b 0.875 c .318 2.410
Total 65           49% 1.627b 1.000c .496 2.020
Escitalopram      
Emslie et al. [62] 154 59 14.5 8 CGI-I RCT 64% 1.605b 1.847c 1.170 2.916
Wagner et al. [63] 129 52 12.6 8 CGI-I RCT 63% 1.541b 1.768c 1.076 2.905
Total 283           64% 1.575b 1.686 c 1.246 2.629
Fluoxetine      
Cornelius et al. [34] 13 77 18.8 12 CGI-I Open 100%   31.154c 1.533 633.140
Emslie et al. [64] 48 46 12.5 8 CGI-I RCT 56% 2.571b 1.286c .576 2.871
Emslie et al. [65] 109 49 12.7 9 CDRS-R RCT 65% 1.626b 1.903c 1.104 3.279
Goodyeret al. (66)a 94 55.3* 14 12 CGI-I Comp. 61% - 1.608c .901 2.867
The TADS Team [67] 109 54 14.6 12 CGI-I RCT 61% 2.873b 1.563c 0.914 2.675
Waslick et al. [68] 12 68 15.9 8 CGI-I Open 75% - 3.000c 0.533 16.897
Total 385           63% 2.239b 1.700c 1.249 2.332
Imipramine      
Bernstein et al. [52] 6 70 14.1 8 CGI-I Comp. 67% - 2.000c 0.194 20.614
Hughes et al. [69] 13 55.3* 14.1* 6 CDRS-R RCT 46% 0.857b 1.000c 0.214 4.674
Keller et al. [70] 94 59 14.9 8 HAM-D RCT 50% 1.175b 1.043c 0.589 1.849
Petti & Law [71] 3 55.3* 9.2 4 SADLI RCT 100% 11.667b 11.667c 0.322 422.139
Puig-Antich et al. [33] 16 60.5 9.1 5 KSADS RCT 56% 0.600b 1.286 c 0.320 5.169
Total 132           52% 1.080b 1.145c 0.693 1.931
Nefazodone      
Findling et al. [72] 28 42 14.2 8 CGI-I Open 79% - 3.667c 1.41 11.787
Goodnick et al. [73] 10 60 15 8 HDRS Open 70% - 2.333c .373 14.613
Total 38           76% - 3.219c 1.181 8.737
Nortriptyline      
Geller et al. [74] 22 27 9.23 8 CDRS-R Open 64% - 1.750 c 0.524 5.842
Geller et al.[75] 12 52 14.3 8 CDRS-R RCT 83% 0.341b 0.091 c 0.009 0.943
Geller et al. [76] 26 30 14.1* 8 KSADS RCT 31% 2.222b 0.444 c 0.143 1.381
Total 60           38% 1.691b 0.660c 0.298 1.451
Paroxetine      
Berard et al. [77] 177 67 15.5 12 MADRS RCT 60% 1.096b 1.581c 1.037 2.410
Braconnier et al. [58] 59 67 16 8 CGI-I Comp. 59% - 1.509 c 0.728 3.125
Emslie et al. [78] 101 47 12 8 CGI-I RCT 49% 1.106b 0.961c 0.554 1.669
Keller et al. [70] 90 62 14.8 8 HAM-D RCT 63% - 1.806c 0.996 3.276
Nobile et al. [79] 7 29 14.4 12 CGI-I Open 71% - 3.333c 0.362 30.701
Total 434           58% 1.308b 1.530c 1.080 1.947
Sertraline      
Melvin et al. [81] 26 73 15 12 GAF Comp. 46% - 0.857 c 0.289 2.546
Nixon et al. [36] 23 87 15 12 HAM-D Open 74% - 3.091c 0.895 10.672
Wagner et al. [81] 185 51 12 10 CDRS-R RCT 69% 1.543b 2.262c 1.481 3.455
Total 234           67% 1.543b 2.073c 1.345 3.100
Venlafaxine      
Brent et al. [82] 166 68 15.8 12 CGI-I Comp. 48% - 0.953c 0.620 1.466
Emslie et al. [83] 169 46 12.2 8 HAM-D RCT 51% 1.103b 1.087 c 0.708 1.669
Total 335           49% 1.103b 1.018c 0.722 1.437
*mean of all included studies used due to missing data
a May not have included only Fluoxetine
b Odds Ratio calculated from Study Placebo Condition
c Odds Ratio Calculated from Estimated Placebo response rate of 49.15%
BDI=Beck Depression Inventory, CDRS-R = Children’s Depression Rating Scale – Revised, CGI-I = Clinical Global Impression – Improvement, HAM-D = Hamilton Rating Scale for Depression, KSADS = Kiddie-Sads, MADRS = Montgomery-Asberg Depression Scale
Table 1: Summary of Included Studies Evaluating Antidepressant Medication in Children and Adolescents.